Amundi Trims Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Amundi decreased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 19.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 48,795 shares of the company’s stock after selling 11,987 shares during the quarter. Amundi’s holdings in Intellia Therapeutics were worth $587,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of NTLA. Capstone Investment Advisors LLC increased its position in shares of Intellia Therapeutics by 1.4% in the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock worth $1,256,000 after acquiring an additional 831 shares in the last quarter. KBC Group NV grew its holdings in Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after purchasing an additional 1,020 shares in the last quarter. Franklin Resources Inc. grew its holdings in Intellia Therapeutics by 10.3% during the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after purchasing an additional 1,538 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Intellia Therapeutics by 14.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock worth $157,000 after acquiring an additional 1,582 shares in the last quarter. Finally, Arizona State Retirement System grew its holdings in Intellia Therapeutics by 6.1% during the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock worth $327,000 after acquiring an additional 1,615 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $8.70 on Friday. The firm’s 50 day moving average is $10.11 and its 200-day moving average is $14.33. The stock has a market capitalization of $900.60 million, a P/E ratio of -1.60 and a beta of 1.97. Intellia Therapeutics, Inc. has a 12-month low of $8.30 and a 12-month high of $28.54.

Insider Buying and Selling

In other news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on NTLA shares. Oppenheimer decreased their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a report on Monday, January 13th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a report on Monday, March 3rd. The Goldman Sachs Group reissued a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a report on Friday, February 28th. Wedbush restated a “neutral” rating and issued a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.56.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.